20 citations,
April 2006 in “Dermatologic Clinics” Antiandrogen therapies are beneficial for treating skin and hair conditions related to androgen levels.
14 citations,
July 1987 in “Dermatologic Clinics” The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.
38 citations,
September 2017 in “Oncologist” Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.
110 citations,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
1 citations,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
16 citations,
September 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
6 citations,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
January 2024 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
30 citations,
January 2000 in “Dermatologic Clinics” Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
1 citations,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
January 2018 in “Springer eBooks” Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.
2 citations,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
76 citations,
July 2011 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.
37 citations,
September 1996 in “Journal of The American Academy of Dermatology” Treat genetic hair loss early with FDA-approved medications and consider hair transplantation.
34 citations,
January 2018 in “International Journal of Dermatology” Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.
February 2018 in “Medicine - Programa De Formación Médica Continuada Acreditado” Minoxidil and finasteride are the main FDA-approved treatments for hair loss, with other methods showing promise but lacking strong evidence.
3 citations,
February 2005 in “Expert Opinion on Investigational Drugs” New treatments for hair loss are being developed using molecular biology.
1 citations,
December 2014 Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
4 citations,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
7 citations,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
3 citations,
April 2011 in “Expert Review of Dermatology” Mesotherapy lacks strong evidence for effectiveness and safety, and its ingredients are not FDA-approved for subcutaneous use.
8 citations,
April 2020 in “Facial Plastic Surgery Clinics of North America” Minoxidil, finasteride, and low-level laser light therapy are effective FDA-approved treatments for hair loss.
2 citations,
January 2019 in “International Journal of Medicine in Developing Countries” Telogen Effluvium is a common hair loss condition, particularly in women, with no specific FDA-approved treatment, and recovery can take up to 18 months.
April 2022 in “Medicina estética” Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
4 citations,
March 2023 in “Current Oncology” Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.
August 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.